Brief: Insilico Medicine & Tenacia Biotechnology Expand AI-Driven CNS Collaboration
26/03/2026 14:37
March 26 (Reuters) - Insilico Medicine Cayman TopCo 3696.HK: INSILICO MEDICINE AND TENACIA BIOTECHNOLOGY EXPAND AI-DRIVEN CNS COLLABORATION WITH DEAL VALUE UP TO US$94.75 MILLION INSILICO MEDICINE CAYMAN TOPCO - CO AND HYGTIA TO SHARE 50/50 GLOBAL RIGHTS; INSILICO ELIGIBLE FOR PAYMENTS OVER HK$500 MILLION INSILICO MEDICINE CAYMAN TOPCO - RECEIVES FDA CLEARANCE TO INITIATE PARKINSON'S DISEASE CLINICAL TRIALS IN JAN 2026 Source text: ID:nPn3jZVZma Further company coverage: 3696.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Insilico Medicine Cayman TopCo
See all newsInSilico Medicine jumps on progress in testing of new weight-loss drug
Development Collaboration
InSilico jumps on collaboration to develop biological frontier foundation models
HK-listed InSilico Medicine climbs as chairman buys shares
Brief: Insilico Medicine Cayman Topco's Chair Purchases Aggregate 113,500 Shares In Sept 4-7